New developments in targeted molecular therapies for glioblastoma

References

• CBTRUS (2008). Statistical report: primary brain tumors in the United States, 2000–2004. Central Brain Tumor Registry of the United States. Hinsdale, IL, USA.
   Google Scholar
• Wen PY, Kesari S. Malignant gliomas in adults. N. Engl. J. Med.359(5), 492–507 (2008).
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol.17(8), 2572–2578 (1999).
   PubMed Web of Science ®Google Scholar
• Lamborn KR, Yung WK, Chang SM et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro. Oncol.10(2), 162–170 (2008).
   PubMed Web of Science ®Google Scholar
• Furnari FB, Fenton T, Bachoo RM et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev.21(21), 2683–2710 (2007).
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature455, 1061–1068 (2008).
   PubMed Web of Science ®Google Scholar
• Idbaih A, Ducray F, Sierra Del Rio M, Hoang-Xuan K, Delattre JY. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors. Oncologist13(9), 978–992 (2008).
   PubMedGoogle Scholar
• Chi A, Wen P. Inhibiting kinases in malignant gliomas. Expert Opin. Ther. Targets11(4), 473–496 (2007).
   PubMed Web of Science ®Google Scholar
• Stommel JM, Kimmelman AC, Ying H et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science318(5848), 287–290 (2007).
   PubMed Web of Science ®Google Scholar
• Mellinghoff I, Wang M, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med.353(19), 2012–2024 (2005).
   PubMed Web of Science ®Google Scholar
• Haas-Kogan D, Prados M, Lamborn K, Tihan T, Berger M, Stokoe D. Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle4(10), 1369–1372 (2005).
   PubMed Web of Science ®Google Scholar
• Brown PD, Krishnan S, Sarkaria JN. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J. Clin. Oncol.26(34), 5603–5609 (2008).
   PubMed Web of Science ®Google Scholar
• Wen P, Chang S, Kuhn J et al. Phase I/II study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 04–02). Neuro Oncol.10, 824 (2008).
   Google Scholar
• Stiles CD, Rowitch DH. Glioma stem cells: a midterm exam. Neuron58(6), 832–846 (2008).
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, McLendon R et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature444, 756–760 (2006).
   PubMed Web of Science ®Google Scholar
• Chang SM, Lamborn KR, Kuhn JG et al. Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro. Oncol.10(4), 631–642 (2008).
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med.285(21), 1182–1186 (1971).
   PubMed Web of Science ®Google Scholar
• Reardon DA, Desjardins A, Rich JN, Vredenburgh JJ. The emerging role of anti-angiogenic therapy for malignant glioma. Curr. Treat. Options Oncol.9(1), 1–22 (2008).
   PubMedGoogle Scholar
• Norden A, Drappatz J, Wen P. Anti-angiogenic therapy in malignant glioma. Curr. Opin. Oncol.20, 652–661 (2008).
   PubMed Web of Science ®Google Scholar
• Cloughesy T, Prados M, Wen P et al. A Phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J. Clin. Oncol.26(Suppl.) (2008) (Abstract 2010b).
   PubMed Web of Science ®Google Scholar
• de Groot JF, Yung WK. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J.14(5), 279–285 (2008).
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol.25(30), 4722–4729 (2007).
   PubMed Web of Science ®Google Scholar
• De Groot JF, Wen PY, Lamborn K et al. Phase II single arm trial of aflibercept in patients with recurrent temozolamide-resistant glioblastoma: NABTC 0601. J. Clin. Oncol.26, 2020 (2008) (Abstract).
   PubMed Web of Science ®Google Scholar
• Batchelor T, Sorensen A, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell11(1), 83–95 (2007).
   PubMed Web of Science ®Google Scholar
• Wen PY, Yung WK, Lamborn KR et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99–08. Clin. Cancer Res.12(16), 4899–4907 (2006).
   PubMed Web of Science ®Google Scholar
• Raymond E, Brandes AA, Dittrich C et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J. Clin. Oncol.26(28), 4659–4665 (2008).
   PubMed Web of Science ®Google Scholar
• Reardon DA, Fink KL, Mikkelsen T et al. Randomized Phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol.26(34), 5610–5617 (2008).
   PubMed Web of Science ®Google Scholar
• Di Tomaso E, Frosch MP, Auluck PK et al. Characterization of blood vessels in brain autopsies of GBM patients who received anti-angiogenic treatment. J. Clin. Oncol.26, 2009 (2008) (Abstract 2009).
   Google Scholar
• Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology70(10), 779–787 (2008).
   PubMed Web of Science ®Google Scholar
• Holash J, Maisonpierre P, Compton D et al. Vessel co-option, regression, and growth in tumors mediated by angiopoietins and VEGF. Science284(5422), 1994–1998 (1999).
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Kim J, Ozawa T et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia2(4), 306–314 (2000).
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer8(8), 592–603 (2008).
   PubMed Web of Science ®Google Scholar
• Hoelzinger DB, Demuth T, Berens ME. Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J. Natl Cancer Inst.99(21), 1583–1593 (2007).
   PubMed Web of Science ®Google Scholar